News
Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...
Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...
20hon MSN
Eli Lilly's Mounjaro met goal of cardiovascular benefit in head-to-head trial with Trulicity
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news from Eli Lilly. Why South Park Did an About-Face on Mocking ...
Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...
Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...
Eli Lilly's Mounjaro demonstrates significant cardiovascular benefits for Type 2 diabetes patients with heart disease, ...
Eli Lilly (LLY) stock in focus as its diabetes drug Mounjaro causes heart benefits suceeding in a late-stage trial versus its ...
Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro was about as good at preventing heart attacks and strokes as its older ...
The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, ...
Weight loss drug giant Eli Lilly and Company (NYSE:LLY)’s shares have struggled in 2025 as they have lost 2.3% year-to-date.
A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results ...
Eli Lilly’s Jaypirca (pirtobrutinib) has been shown to be superior to Johnson & Johnson (J&J) and AbbVie’s star Bruton's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback